SENS-AI
UPL Results Bearish

UNIVERSAL PARTNERS LIMITED - Summarised unaudited financial statements for the quarter ended 30 September 2026

Universal Partners Limited
Full analysis

What this filing means

A £12.8 million write-down on the PortmanDentex stake turns a modest quarter into a heavy one. Universal Partners reports a £13.08 million quarterly loss and a 16.5% year-on-year fall in NAV per share to £0.979, driven almost entirely by the PD fair-value cut after revenue and EBITDA came in below plan. The rest of the portfolio is doing better — Workwell grew like-for-like and Xcede is ahead of expectations — but the PD deterioration dominates the numbers and the read.

Universal Partners holds stakes in private companies and reports what those stakes are worth each quarter. This quarter, one of its investments—a dental group called PortmanDentex—was marked down by £12.8 million because trading was weak. That single write-down pushed the whole company into a £13 million loss and knocked its net asset value down by about 16% from a year ago. The other investments are mostly doing fine, but the dental one is the problem child right now.

Bull case

  • WW delivered like-for-like revenue and EBITDA growth in the final quarter, with the issuer describing it as a clear step-up from historical growth rates.
  • Xcede's first nine-month trading remained ahead of expectations, with EBITDA significantly ahead of the same period last year and the third quarter the strongest of the year to date.
  • Xcede recorded its highest number of permanent placements for the year to date in September and ended the period with a strong pipeline into the final quarter.
  • UPL received USD 5.42 million from the SC Lowy transaction and applied the proceeds to reduce its RMB term-loan facility.
  • The SC Lowy transaction is expected to generate total proceeds of more than USD 15 million, equal to UPL's initial investment cost, with 7% annual interest payable on the loan notes.

Bear case

  • NAV per share fell to £0.979 from £1.172 a year earlier and £1.158 at 30 June 2026.
  • UPL reported a quarterly loss of (13 078 723) GBP and loss per share of (17.925) pence.
  • PD's £12.8 million write-down reflects negative performance, with its valuation to be reassessed at the end of the next quarter.
  • PD revenue and EBITDA were below plan for the year ended 30 September 2026 amid weaker markets and reduced hours worked by experienced clinicians.
  • Xcede's contractor numbers and margins remain key areas of focus despite stronger permanent recruitment.

AI-generated summary by SENS-AI, based on the original JSE SENS filing.

SENS-AI conclusion

The PD write-down is the story, and it is a genuine deterioration, not a technical adjustment: revenue and EBITDA were below plan, and the valuation will be reassessed next quarter, leaving room for further cuts. The WW and Xcede strength is real but does not offset a £12.8 million fair-value write-down on the largest problem asset. The read is Bearish on the NAV erosion and the open question of whether PD stabilises. So what: the market still needs evidence that PD's turnaround is working before the NAV decline can be treated as a one-off rather than the start of a trend.

The next quarterly update will show whether the PD valuation holds or is cut again, and whether the turnaround plan is gaining traction.

Evidence from the filing

  • WW delivered like-for-like revenue and EBITDA growth in the final quarter, with the issuer describing it as a clear step-up from historical growth rates.

    “Trading momentum strengthened through the final quarter of WW's financial year to September 2026, and both revenue and EBITDA grew on a like-for-like basis, a clear step up from historical growth rates.”

  • Xcede's first nine-month trading remained ahead of expectations, with EBITDA significantly ahead of the same period last year and the third quarter the strongest of the year to date.

    “Trading for the first nine months of the financial year to December 2026 remained ahead of expectations, with EBITDA significantly ahead of the same period last year. The third quarter was the strongest of the year to date, although slightly behind a budget weighted towards the second half, as lower contract income, particularly in EarthStream, offset continued strength in permanent recruitment.”

  • Xcede recorded its highest number of permanent placements for the year to date in September and ended the period with a strong pipeline into the final quarter.

    “September delivered the highest number of permanent placements of the year to date and a strong pipeline going into the final quarter. Xcede UK remained the standout performer, offsetting softer performances in other parts of the group. Contractor numbers and margins remain the key area of focus.”

  • UPL received USD 5.42 million from the SC Lowy transaction and applied the proceeds to reduce its RMB term-loan facility.

    “To date, UPL has received cash proceeds of USD 5.42 million under the agreement. These proceeds have been used to reduce the term loan facility provided by RMB. A further minimum payment of USD 2.17 million is due by 31 August 2027, with the full outstanding balance, including accrued interest, due by 31 August 2028.”

  • The SC Lowy transaction is expected to generate total proceeds of more than USD 15 million, equal to UPL's initial investment cost, with 7% annual interest payable on the loan notes.

    “Interest is payable on the loan notes at 7% per annum, and UPL expects to receive total proceeds of more than USD 15 million, being the initial cost of the investment.”

  • NAV per share fell to £0.979 from £1.172 a year earlier and £1.158 at 30 June 2026.

    “Net asset value per share ("NAV") GBP £ 0.979 £ 1.172 £ 1.158”

  • UPL reported a quarterly loss of (13 078 723) GBP and loss per share of (17.925) pence.

    “ Loss for the quarter / year GBP (13 078 723) (330 553) (1 338 363)”

  • PD's £12.8 million write-down reflects negative performance, with its valuation to be reassessed at the end of the next quarter.

    “During the quarter, an annual independent valuation of PD was prepared. Considering this valuation and the current negative performance of the business, UPL has written down the fair value of its investment in PD by £12.8 million. Turnaround progress is being monitored closely, and the valuation will be reassessed at the end of the next quarter.”

  • PD revenue and EBITDA were below plan for the year ended 30 September 2026 amid weaker markets and reduced hours worked by experienced clinicians.

    “Challenging trading conditions continued during the final quarter, particularly in PD’s core UK market. For the year ended 30 September 2026, revenue and EBITDA were below plan, reflecting weaker market conditions and reduced hours worked by experienced clinicians.”
Category
Results
Event posture
Bearish Continuation
Published
Nov 11, 2026

More on Universal Partners Limited

Universal Partners Limited (UPL) share price All Universal Partners Limited SENS announcements

Related filings